-
J.
Scandura,
G.
Roboz,
Michelle
Moh,
E.
Morawa,
F.
Brenet,
J.
Bose,
Luis
Villegas,
Usama
Gergis,
Sebastian
Mayer,
Cindy
Ippoliti,
T.
Curcio,
Ellen
Ritchie,
Eric
Feldman
(2011)
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Blood, 118 6
-
R.
Siegel,
Elizabeth
Ward,
O.
Brawley,
A.
Jemal
(2011)
Cancer statistics, 2011
CA: A Cancer Journal for Clinicians, 61
-
J.
Karp,
A.
Blackford,
B.
Smith,
Katrina
Alino,
A.
Seung,
J.
Bolaños-Meade,
J.
Greer,
H.
Carraway,
S.
Gore,
Richard
Jones,
M.
Levis,
M.
McDevitt,
L.
Doyle,
J.
Wright
(2010)
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Leukemia research, 34 7
-
T.
Kindler,
D.
Lipka,
T.
Fischer
(2010)
FLT3 as a therapeutic target in AML: still challenging after all these years.
Blood, 116 24
-
Michael
Martin,
G.
Uy,
Elizabeth
Procknow,
K.
Stockerl-Goldstein,
A.
Cashen,
P.
Westervelt,
C.
Abboud,
K.
Augustin,
Jingqin
Luo,
J.
Dipersio,
R.
Vij
(2009)
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG
Bone Marrow Transplantation, 44
-
By
Grimwade,
H.
Walker,
F.
Oliver,
K.
Wheatley,
C.
Harrison,
G.
Harrison,
J.
Rees,
I.
Hann,
R.
Stevens,
A.
Burnett,
A.
Goldstone
(1998)
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Blood, 92 7
-
H.
Naina,
M.
Patnaik,
S.
Harris
(2009)
Anthracycline dose intensification in acute myeloid leukemia.
The New England journal of medicine, 361 26
-
S.
Farag,
K.
Archer,
K.
Mrózek,
A.
Ruppert,
A.
Carroll,
J.
Vardiman,
M.
Pettenati,
M.
Baer,
M.
Qumsiyeh,
Prasad
Koduru,
Yi
Ning,
Robert
Mayer,
Richard
Stone,
Richard
Larson,
C.
Bloomfield
(2006)
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Blood, 108 1
-
S.
Faderl,
F.
Ravandi,
Xuelin
Huang,
G.
Garcia-Manero,
A.
Ferrajoli,
Z.
Estrov,
G.
Borthakur,
S.
Verstovsek,
D.
Thomas,
M.
Kwari,
H.
Kantarjian
(2008)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Blood, 112 5
-
T.
Lin,
Qiuju
Wang,
P.
Brown,
C.
Peacock,
Akil
Merchant,
Sarah
Brennan,
Evan
Jones,
Karen
McGovern,
D.
Watkins,
K.
Sakamoto,
W.
Matsui,
R.
Means
(2008)
Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926
PLoS ONE, 5
-
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
-
J.
Cortes,
E.
Feldman,
S.
Goldberg,
D.
Rizzieri,
Kim
Paulsen,
A.
Louie,
J.
Kolitz
(2011)
CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report
Blood, 118
-
C.
Dierks,
Jovana
Grbić,
K.
Zirlik,
R.
Beigi,
N.
Englund,
G.
Guo,
H.
Veelken,
M.
Engelhardt,
R.
Mertelsmann,
J.
Kelleher,
Peter
Schultz,
M.
Warmuth
(2007)
Essential role of stromally induced hedgehog signaling in B-cell malignancies
Nature Medicine, 13
-
M.
Levis,
F.
Ravandi,
E.
Wang,
M.
Baer,
A.
Perl,
S.
Coutre,
H.
Erba,
R.
Stuart,
M.
Baccarani,
L.
Cripe,
M.
Tallman,
G.
Meloni,
L.
Godley,
A.
Langston,
S.
Amadori,
I.
Lewis,
A.
Nagler,
R.
Stone,
K.
Yee,
A.
Advani,
D.
Douer,
W.
Wiktor-Jedrzejczak,
G.
Juliusson,
M.
Litzow,
S.
Petersdorf,
M.
Sanz,
H.
Kantarjian,
Takashi
Sato,
L.
Tremmel,
D.
Bensen-Kennedy,
D.
Small,
B.
Smith
(2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Blood, 117 12
-
S.
Fröhling,
R.
Schlenk,
I.
Stolze,
Jörg
Bihlmayr,
A.
Benner,
S.
Kreitmeier,
K.
Tobis,
H.
Döhner,
K.
Döhner
(2004)
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 4
-
M.
Sekeres,
H.
Gundacker,
J.
Lancet,
A.
Advani,
S.
Petersdorf,
J.
Liesveld,
D.
Mulford,
T.
Norwood,
C.
Willman,
F.
Appelbaum,
A.
List
(2011)
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
Blood, 118 3
-
A.
Burnett,
N.
Russell,
J.
Kell,
M.
Dennis,
D.
Milligan,
S.
Paolini,
J.
Yin,
D.
Culligan,
P.
Johnston,
John
Murphy,
M.
McMullin,
A.
Hunter,
E.
Das‐Gupta,
R.
Clark,
R.
Carr,
R.
Hills
(2010)
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 14
-
S.
Buchholz,
E.
Dammann,
M.
Stadler,
J.
Krauter,
G.
Beutel,
A.
Trummer,
M.
Eder,
A.
Ganser
(2012)
Cytoreductive treatment with clofarabine/ara‐C combined with reduced‐intensity conditioning and allogeneic stem cell transplantation in patients with high‐risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome
European Journal of Haematology, 88
-
S.
Chowdhury,
S.
Seropian,
P.
Marks
(2009)
Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia
American Journal of Hematology, 84
-
S.
Fröhling,
R.
Schlenk,
J.
Breitruck,
A.
Benner,
S.
Kreitmeier,
K.
Tobis,
H.
Döhner,
K.
Döhner
(2002)
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.
Blood, 100 13
-
J.
Byrd,
K.
Mrózek,
R.
Dodge,
A.
Carroll,
C.
Edwards,
D.
Arthur,
M.
Pettenati,
S.
Patil,
K.
Rao,
M.
Watson,
P.
Koduru,
J.
Moore,
R.
Stone,
R.
Mayer,
E.
Feldman,
F.
Davey,
C.
Schiffer,
R.
Larson,
C.
Bloomfield
(2002)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Blood, 100 13
-
Dr.
Nurul,
Akhtar
Hasan,
Mohammad
Mamun
(2007)
Leading article
-
H.
Kantarjian,
H.
Erba,
D.
Claxton,
M.
Arellano,
R.
Lyons,
T.
Kovascovics,
J.
Gabrilove,
M.
Craig,
D.
Douer,
M.
Maris,
S.
Petersdorf,
P.
Shami,
A.
Yeager,
S.
Eckert,
R.
Abichandani,
S.
Faderl
(2010)
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
-
T.
Graef,
A.
Kuendgen,
R.
Fenk,
F.
Zohren,
R.
Haas,
G.
Kobbe
(2007)
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
Leukemia research, 31 2
-
A.
Fathi,
B.
Chabner
(2011)
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
The oncologist, 16 8
-
M.
Škrtić,
S.
Sriskanthadevan,
Bozhena
Jhas,
M.
Gebbia,
Xiaoming
Wang,
Zezhou
Wang,
R.
Hurren,
Y.
Jitkova,
M.
Gronda,
N.
Maclean,
Courteney
Lai,
Y.
Eberhard,
Justyna
Bartoszko,
P.
Spagnuolo,
A.
Rutledge,
A.
Datti,
T.
Ketela,
J.
Moffat,
B.
Robinson,
Jessie
Cameron,
J.
Wrana,
C.
Eaves,
M.
Minden,
Jean
Wang,
J.
Dick,
K.
Humphries,
C.
Nislow,
G.
Giaever,
A.
Schimmer
(2011)
Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.
Cancer cell, 20 5
-
J.
Karp,
B.
Smith,
I.
Gojo,
J.
Lancet,
J.
Greer,
M.
Klein,
L.
Morris,
M.
Levis,
S.
Gore,
J.
Wright,
E.
Garrett-Mayer
(2008)
Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features
Clinical Cancer Research, 14
-
A.
Wei,
P.
Tan,
J.
Catalano,
P.
Walker,
A.
Schwarer,
S.
Avery,
S.
Patil,
Stephen
Opat,
N.
Cummings,
A.
Spencer
(2011)
Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML
Blood, 118
-
A.
Burnett,
D.
Linch
(2007)
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML
-
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.
-
A.
Cashen,
G.
Schiller,
M.
O'donnell,
J.
Dipersio
(2010)
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
-
K.
Rai,
J.
Holland,
O.
Glidewell,
V.
Weinberg,
K.
Brunner,
JP
Obrecht,
H.
Preisler,
IW
Nawabi,
D.
Prager,
R.
Carey,
Cooper,
F.
Haurani,
JL
Hutchison,
R.
Silver,
G.
Falkson,
P.
Wiernik,
H.
Hoagland,
C.
Bloomfield,
G.
James,
A.
Gottlieb,
SV
Ramanan,
J.
Blom,
N.
Nissen,
Arthur
Bank,
R.
Ellison,
F.
Kung,
P.
Henry,
O.
Mcintyre,
SK
Kaan
(1981)
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B.
Blood, 58 6
-
S.
Faderl,
S.
Verstovsek,
J.
Cortes,
F.
Ravandi,
M.
Beran,
G.
Garcia-Manero,
A.
Ferrajoli,
Z.
Estrov,
S.
O'brien,
C.
Koller,
F.
Giles,
W.
Wierda,
M.
Kwari,
H.
Kantarjian
(2006)
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood, 108 1
-
NCCN Practice Guidelines in Oncology v.2
-
S.
Faderl,
V.
Gandhi,
S.
O'brien,
P.
Bonate,
J.
Cortes,
E.
Estey,
M.
Beran,
W.
Wierda,
G.
Garcia-Manero,
A.
Ferrajoli,
Z.
Estrov,
F.
Giles,
M.
Du,
M.
Kwari,
M.
Keating,
W.
Plunkett,
H.
Kantarjian
(2005)
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood, 105 3
-
J.
Delaunay,
C.
Récher,
A.
Pigneux,
F.
Witz,
N.
Vey,
O.
Blanchet,
P.
Lefebvre,
I.
Luquet,
Isabelle
Guillerme,
C.
Volteau,
E.
Gyan,
B.
Lioure,
E.
Jourdan,
D.
Bouscary,
R.
Guièze,
Edouard
Randriamalala,
M.
Uribe,
F.
Dreyfus,
C.
Lacombe,
M.
Béné,
J.
Cahn,
J.
Harousseau,
N.
Ifrah
(2011)
Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study
Blood, 118
-
J.
Menzin,
K.
Lang,
C.
Earle,
D.
Kerney,
R.
Mallick
(2002)
The outcomes and costs of acute myeloid leukemia among the elderly.
Archives of internal medicine, 162 14
-
T.
Lapidot,
C.
Sirard,
J.
Vormoor,
B.
Murdoch,
T.
Hoang,
J.
Cáceres-Cortés,
M.
Minden,
B.
Paterson,
M.
Caligiuri,
J.
Dick
(1994)
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Nature, 367
-
C.
Peacock,
Qiuju
Wang,
Gregory
Gesell,
Ian
Corcoran-Schwartz,
Evan
Jones,
Jynho
Kim,
Jynho
Kim,
W.
Devereux,
J.
Rhodes,
C.
Huff,
P.
Beachy,
P.
Beachy,
D.
Watkins,
W.
Matsui
(2007)
Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
Proceedings of the National Academy of Sciences, 104
-
R.
Mayer,
Roger
Davis,
C.
Schiffer,
D.
Berg,
B.
Powell,
P.
Schulman,
G.
Omura,
J.
Moore,
O.
Mcintyre,
E.
Frei
(1994)
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
The New England journal of medicine, 331 14
-
Rajesh
Singh,
J.
Kim,
Yogesh
Davuluri,
E.
Drakos,
J.
Cho-Vega,
Hesham
Amin,
F.
Vega
(2010)
Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation
Leukemia, 24
-
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
-
M.
Buyse,
P.
Squifflet,
B.
Lange,
T.
Alonzo,
R.
Larson,
J.
Kolitz,
S.
George,
C.
Bloomfield,
S.
Castaigne,
S.
Chevret,
D.
Blaise,
D.
Maraninchi,
K.
Lucchesi,
T.
Burzykowski
(2011)
Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.
Blood, 117 26
-
J.
Vardiman,
J.
Thiele,
D.
Arber,
R.
Brunning,
M.
Borowitz,
A.
Porwit,
N.
Harris,
M.
Beau,
E.
Hellström-Lindberg,
A.
Tefferi,
C.
Bloomfield
(2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
Blood, 114 5
-
M.
Bornhäuser,
T.
Illmer,
M.
Schaich,
S.
Soucek,
G.
Ehninger,
C.
Thiede
(2007)
Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.
Blood, 109 5
-
M.
Bienz,
M.
Ludwig,
B.
Mueller,
E.
Leibundgut,
D.
Ratschiller,
M.
Solenthaler,
M.
Fey,
T.
Pabst
(2005)
Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype
Clinical Cancer Research, 11
-
R.
Schlenk,
K.
Döhner,
J.
Krauter,
S.
Fröhling,
A.
Corbacioglu,
L.
Bullinger,
Marianne
Habdank,
D.
Späth,
M.
Morgan,
A.
Benner,
B.
Schlegelberger,
G.
Heil,
A.
Ganser,
H.
Döhner
(2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
The New England journal of medicine, 358 18
-
Wahseng
Lim,
P.
Tardi,
N.
Santos,
Xiaowei
Xie,
M.
Fan,
B.
Liboiron,
Xiao‐bin
Huang,
T.
Harasym,
D.
Bermudes,
L.
Mayer
(2010)
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.
Leukemia research, 34 9
-
J.
Karp,
A.
Passaniti,
I.
Gojo,
S.
Kaufmann,
K.
Bible,
T.
Garimella,
J.
Greer,
J.
Greer,
Janet
Briel,
B.
Smith,
S.
Gore,
M.
Tidwell,
D.
Ross,
J.
Wright,
A.
Colevas,
K.
Bauer
(2005)
Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-β-d-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias
Clinical Cancer Research, 11
-
R.
Walter,
M.
Othus,
G.
Borthakur,
F.
Ravandi,
J.
Cortes,
S.
Pierce,
F.
Appelbaum,
H.
Kantarjian,
E.
Estey
(2011)
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 33
-
S.
Castaigne,
C.
Pautas,
C.
Terré,
E.
Raffoux,
D.
Bordessoule,
J.
Bastie,
O.
Legrand,
X.
Thomas,
P.
Turlure,
O.
Reman,
T.
Revel,
L.
Gastaud,
C.
Gardin,
L.
Sutton,
J.
Marolleau,
S.
Botton,
O.
Hermine,
I.
Plantier,
M.
Janvier,
B.
Dupriez,
M.
Simon,
Noémie
Gunzburg,
Stephanie
Foucault-Haiat,
N.
Contentin,
C.
Berthon,
P.
Fenaux,
Estelle
Henry,
P.
Rousselot,
C.
Preudhomme,
S.
Chevret,
H.
Dombret
(2011)
Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)
Blood, 118
-
M.
Sanz,
F.
Lo‐Coco
(2011)
Modern approaches to treating acute promyelocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 5
-
A.
Burnett,
R.
Hills,
D.
Milligan,
L.
Kjeldsen,
J.
Kell,
N.
Russell,
J.
Yin,
A.
Hunter,
A.
Goldstone,
K.
Wheatley
(2011)
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 4
-
Yates
Jw,
Wallace
Hj,
R.
Ellison,
J.
Holland
(1973)
Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.
Cancer chemotherapy reports, 57 4
-
G.
Garcia-Manero,
F.
Tambaro,
Nebiyou
Bekele,
Hui
Yang,
F.
Ravandi,
E.
Jabbour,
G.
Borthakur,
T.
Kadia,
M.
Konopleva,
S.
Faderl,
J.
Cortes,
M.
Brandt,
Yumin
Hu,
Deborah
McCue,
W.
Newsome,
S.
Pierce,
Marcos
DeLima,
H.
Kantarjian
(2011)
Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Blood, 118
-
S.
Faderl,
M.
Wetzler,
D.
Rizzieri,
G.
Schiller,
M.
Jagasia,
R.
Stuart,
S.
Ganguly,
D.
Avigan,
M.
Craig,
R.
Collins,
M.
Maris,
T.
Kovacsovics,
S.
Goldberg,
K.
Seiter,
P.
Hari,
F.
Ravandi,
E.
Wang,
S.
Eckert,
D.
Huebner,
H.
Kantarjian
(2011)
Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
K.
Mrózek,
G.
Marcucci,
P.
Paschka,
S.
Whitman,
C.
Bloomfield
(2007)
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
Blood, 109 2
-
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
-
T.
Büchner,
U.
Krug,
W.
Berdel,
A.
Heinecke,
M.
Sauerland,
B.
Wörmann,
W.
Hiddemann
(2007)
Maintenance for Acute Myeloid Leukemia Revisited
Current Treatment Options in Oncology, 8
-
(2010)
NCCN Practice Guidelines in Oncology v.2.2010
Acute Myeloid Leukemia
-
P.
Paschka,
G.
Marcucci,
A.
Ruppert,
K.
Mrózek,
Hankui
Chen,
R.
Kittles,
T.
Vukosavljevic,
D.
Perrotti,
J.
Vardiman,
A.
Carroll,
J.
Kolitz,
R.
Larson,
C.
Bloomfield
(2006)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 24
-
M.
Slovak,
K.
Kopecky,
P.
Cassileth,
D.
Harrington,
Karl
Theil,
Anwar
Mohamed,
E.
Paietta,
C.
Willman,
David
Head,
Jacob
Rowe,
Stephen
Forman,
Frederick
Appelbaum
(2000)
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Blood, 96 13
-
B.
Löwenberg,
G.
Ossenkoppele,
W.
Putten,
H.
Schouten,
C.
Graux,
A.
Ferrant,
P.
Sonneveld,
J.
Maertens,
M.
Jongen‐Lavrencic,
M.
Lilienfeld-Toal,
B.
Biemond,
E.
Vellenga,
M.
Kooy,
L.
Verdonck,
J.
Beck,
H.
Döhner,
A.
Gratwohl,
T.
Pabst,
G.
Verhoef
(2009)
High-dose daunorubicin in older patients with acute myeloid leukemia.
The New England journal of medicine, 361 13
-
J.
Magenau,
H.
Tobai,
A.
Pawarode,
T.
Braun,
E.
Peres,
P.
Reddy,
C.
Kitko,
S.
Choi,
G.
Yanik,
D.
Frame,
Andrew
Harris,
H.
Erba,
Lisa
Kujawski,
K.
Elenitoba-Johnson,
Jennifer
Sanks,
Dawn
Jones,
S.
Paczesny,
J.
Ferrara,
J.
Levine,
S.
Mineishi
(2011)
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Blood, 118 15
-
M.
Baer,
S.
George,
M.
Caligiuri,
B.
Sanford,
Sandra
Bothun,
K.
Mrózek,
J.
Kolitz,
B.
Powell,
J.
Moore,
R.
Stone,
J.
Anastasi,
C.
Bloomfield,
R.
Larson
(2008)
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 30
-
C.
Pautas,
F.
Merabet,
X.
Thomas,
E.
Raffoux,
C.
Gardin,
S.
Corm,
J.
Bourhis,
O.
Reman,
P.
Turlure,
N.
Contentin,
T.
Revel,
P.
Rousselot,
C.
Preudhomme,
D.
Bordessoule,
P.
Fenaux,
C.
Terré,
M.
Michallet,
H.
Dombret,
S.
Chevret,
S.
Castaigne
(2010)
Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 5
-
Abstr 6503
-
D.
Breems,
W.
Putten,
P.
Huijgens,
G.
Ossenkoppele,
G.
Verhoef,
L.
Verdonck,
E.
Vellenga,
G.
Greef,
E.
Jacky,
J.
Lelie,
M.
Boogaerts,
B.
Löwenberg
(2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 9
-
R.
Care,
P.
Valk,
A.
Goodeve,
Faisel
Abu‐Duhier,
W.
Geertsma‐Kleinekoort,
G.
Wilson,
M.
Gari,
I.
Peake,
B.
Löwenberg,
J.
Reilly
(2003)
Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
British Journal of Haematology, 121
-
P.
Fenaux,
G.
Mufti,
E.
Hellström-Lindberg,
V.
Santini,
N.
Gattermann,
U.
Germing,
G.
Sanz,
A.
List,
S.
Gore,
J.
Seymour,
H.
Dombret,
J.
Backstrom,
L.
Zimmerman,
D.
McKenzie,
C.
Beach,
L.
Silverman
(2010)
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
-
B.
Falini,
C.
Mecucci,
E.
Tiacci,
M.
Alcalay,
R.
Rosati,
L.
Pasqualucci,
R.
Starza,
D.
Diverio,
E.
Colombo,
A.
Santucci,
B.
Bigerna,
R.
Pacini,
A.
Pucciarini,
A.
Liso,
M.
Vignetti,
P.
Fazi,
Natalia
Meani,
V.
Pettirossi,
G.
Saglio,
F.
Mandelli,
F.
Lo‐Coco,
P.
Pelicci,
M.
Martelli
(2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
The New England journal of medicine, 352 3
-
A.
DeZern,
A.
Sung,
S.‐H.
Kim,
B.
Smith,
Judith
Karp,
Steven
Gore,
Richard
Jones,
E.
Fuchs,
L.
Luznik,
M.
McDevitt,
M.
Levis
(2011)
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 9
-
W.
Blum,
R.
Klisovic,
H.
Becker,
Xiaoxia
Yang,
Darlene
Rozewski,
M.
Phelps,
R.
Garzon,
A.
Walker,
J.
Chandler,
S.
Whitman,
John
Curfman,
Shujun
Liu,
L.
Schaaf,
J.
Mickle,
C.
Kefauver,
S.
Devine,
M.
Grever,
G.
Marcucci,
J.
Byrd
(2010)
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 33
-
H.
Kantarjian,
V.
Gandhi,
J.
Cortes,
S.
Verstovsek,
M.
Du,
G.
Garcia-Manero,
F.
Giles,
S.
Faderl,
S.
O'brien,
S.
Jeha,
Jan
Davis,
Z.
Shaked,
A.
Craig,
M.
Keating,
W.
Plunkett,
E.
Freireich
(2003)
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Blood, 102 7
-
C.
Jamieson,
J.
Cortes,
V.
Oehler,
M.
Baccarani,
H.
Kantarjian,
C.
Papayannidis,
K.
Rice,
Xiaoxi
Zhang,
N.
Shaik,
R.
Courtney,
W.
Levin,
G.
Martinelli
(2011)
Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies
Blood, 118
-
G.
Uy,
M.
Rettig,
Ibraheem
Motabi,
K.
Mcfarland,
K.
Trinkaus,
Lindsay
Hladnik,
Shashikant
Kulkarni,
Camille
Abboud,
A.
Cashen,
K.
Stockerl-Goldstein,
Ravi
Vij,
P.
Westervelt,
J.
Dipersio
(2012)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Blood, 119 17
-
C.
Schiffer
(2010)
"I am older, not elderly," said the patient with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
-
S.
Amadori,
R.
Stasi,
A.
Martelli,
A.
Venditti,
G.
Meloni,
F.
Pane,
G.
Martinelli,
M.
Lunghi,
L.
Pagano,
D.
Cilloni,
E.
Rossetti,
F.
Raimondo,
C.
Fozza,
L.
Annino,
F.
Chiarini,
F.
Ricci,
E.
Ammatuna,
E.
Sala,
P.
Fazi,
M.
Vignetti
(2012)
Temsirolimus, an mTOR inhibitor, in combination with lower‐dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML‐1107)
British Journal of Haematology, 156
-
D.
Bonnet,
J.
Dick
(1997)
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Nature Medicine, 3
-
(2008)
Review Articles (434 articles)
-
F.
Ravandi,
J.
Issa,
G.
Garcia-Manero,
S.
O'brien,
S.
Pierce,
J.
Shan,
G.
Borthakur,
S.
Verstovsek,
S.
Faderl,
J.
Cortes,
H.
Kantarjian
(2009)
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
Cancer, 115
-
P.
Beachy,
S.
Karhadkar,
D.
Berman
(2004)
Tissue repair and stem cell renewal in carcinogenesis
Nature, 432
-
P.
Cassileth,
E.
Lynch,
J.
Hines,
M.
Oken,
Joseph,
J.,
Mazza,
J.
Bennett,
P.
Mcglave,
M.
Edelstein,
D.
Harrington
(1992)
Varying intensity of postremission therapy in acute myeloid leukemia.
Blood, 79 8
-
Chen
Zhao,
Alan
Chen,
C.
Jamieson,
M.
Fereshteh,
Annelie
Abrahamsson,
Jordan
Blum,
H.
Kwon,
Jynho
Kim,
J.
Chute,
D.
Rizzieri,
M.
Munchhof,
T.
Vanarsdale,
P.
Beachy,
T.
Reya
(2009)
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Nature, 460
-
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.
-
F.
Appelbaum,
H.
Gundacker,
D.
Head,
M.
Slovak,
C.
Willman,
J.
Godwin,
J.
Anderson,
S.
Petersdorf
(2006)
Age and acute myeloid leukemia.
Blood, 107 9
-
B.
Andersson,
B.
Valdez,
M.
Lima,
Xuemei
Wang,
P.
Thall,
L.
Worth,
U.
Popat,
T.
Madden,
C.
Hosing,
A.
Alousi,
G.
Rondon,
P.
Kebriaei,
E.
Shpall,
Roy
Jones,
R.
Champlin
(2011)
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 17 6
-
A.
Goldstone,
A.
Burnett,
K.
Wheatley,
Alastair
Smith,
R.
Hutchinson,
R.
Clark
(2001)
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
Blood, 98 5
-
A.
Burnett,
R.
Hills,
A.
Hunter,
D.
Milligan,
W.
Kell,
K.
Wheatley,
J.
Yin,
Sahra
Ali,
L.
Kjeldsen,
D.
Bowen,
N.
Russell
(2011)
The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial
Blood, 118
-
J.
Taipale,
P.
Beachy
(2001)
The Hedgehog and Wnt signalling pathways in cancer
Nature, 411
-
(2010)
Practice Guidelines in Oncology v.2.2010. Acute Myeloid Leukemia